Skip to main content
SpringerLink
Log in

The Art of Stem Cell-Based Therapy

  • Chapter
  • First Online:
Potency Assays for Advanced Stem Cell Therapy Medicinal Products

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1420))

Abstract

Potency assays represent crucial experiments at the hub of the comprehensive complexity surrounding cell therapy. Moreover, numerous factors beyond biological and scientific considerations are involved in achieving successful potency assays that fulfil regulatory authority approval for a new advanced therapy medicinal product. Though this can mean a frustratingly long period of discovery and development, progress in cell therapy is nowadays proceeding remarkably quickly, assisted by the potency assay rigorously placing emphasis on the need to critically analyse the key factor/s responsible for the therapeutic mechanism of action. History has shown that it can take many decades for there to be an improved understanding of a mechanism of action. Yet the chasing of precise targets has revolutionised medicine, with no clearer example than approaches to viral pandemics. The centuries involved in the eradication of smallpox have paved the way for an unprecedented pace of vaccine development for the Covid-19 pandemic. Such extraordinary accomplishments foster encouragement that similarly for stem cell-based therapy, our scientific knowledge will continue to improve apace. This chapter focuses on the art of experimentation and discovery, introducing potency assay requisites and numerous factors that can influence potency assay outcomes. A comprehensive understanding of potency assays and their development can hasten the provision of new cell therapies to help resolve burdensome diseases of unmet medical need.

Yet an experiment, were you to try it, could free you from your cavil–and the source of your arts’ course springs from experiment.

Dante Alighieri, The Divine Comedy, Paradiso, Canto II, lines 94-96, c. 1304-1321. English translation by Allen Mandelbaum.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Aboalola D, Badraiq H, Alsiary R, Zakri S, Aboulola N, Haneef L, Malibari D, Baadhaim M, Alsayegh K (2022) An infodemic of misinformation on stem cell therapy among the population of Saudi Arabia: a cross-sectional study. Front Med 9:789695

    Article  Google Scholar 

  2. Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S (2020) Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health emergency. Sci Total Environ 730:138996

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Anderson AJ, Cummings BJ (2016) Achieving informed consent for cellular therapies: a preclinical translational research perspective on regulations versus a dose of reality. J Law Med Ethics 44:394–401

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ansari Z, Kuriyan A, Albini T (2017) Unproven stem cell therapy for macular degeneration. Oncotarget 8:90636

    Article  PubMed  PubMed Central  Google Scholar 

  5. Anthony E, Lovell-Badge R, Morrison SJ (2021) New guidelines for stem cell and embryo research from the ISSCR. Cell Stem Cell 28:991–992

    Article  CAS  PubMed  Google Scholar 

  6. Assen LS, Jongsma KR, Isasi R, Tryfonidou MA, Bredenoord AL (2021) Recognizing the ethical implications of stem cell research: a call for broadening the scope. Stem Cell Reports 16:1656–1661

    Article  PubMed  PubMed Central  Google Scholar 

  7. Bauer G, Elsallab M, Abou-El-Enein M (2018) Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Transl Med 7:676–685

    Article  PubMed  PubMed Central  Google Scholar 

  8. Baylis F (2021) ISSCR guidelines fudge heritable human-genome editing. Nature 594:333

    Article  CAS  PubMed  Google Scholar 

  9. Bersenev A, Gustafson MP, Hanley PJ (2022) ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy products. Cytotherapy 24:27–31

    Article  CAS  PubMed  Google Scholar 

  10. Boland LK, Burand AJ, Boyt DT, Dobroski H, Di L, Liszewski JN, Schrodt MV, Frazer MK, Santillan DA, Ankrum JA (2019) Nature vs. nurture: defining the effects of mesenchymal stromal cell isolation and culture conditions on resiliency to palmitate challenge. Front Immunol 10:1080

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bravery CA, Carmen J, Fong T, Oprea W, Hoogendoorn KH, Woda J, Burger SR, Rowley JA, Bonyhadi ML, Van’t Hof W (2013) Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. Cytotherapy 15:9–19.e9

    Article  PubMed  Google Scholar 

  12. Chinnadurai R, Bates PD, Kunugi KA, Nickel KP, DeWerd LA, Capitini CM, Galipeau J, Kimple RJ (2021) Dichotomic potency of IFNγ licensed allogeneic mesenchymal stromal cells in animal models of acute radiation syndrome and graft versus host disease. Front Immunol 12:708950

    Article  PubMed  PubMed Central  Google Scholar 

  13. Chouw A, Milanda T, Sartika CR, Kirana MN, Halim D, Faried A (2022) Potency of mesenchymal stem cell and its secretome in treating COVID-19. Regen Eng Transl Med 8:43–54

    Article  CAS  PubMed  Google Scholar 

  14. Cohen J (2022) First self-copying mRNA vaccine proves itself in pandemic trial. Science 376:446

    Article  CAS  PubMed  Google Scholar 

  15. Cuende N, Ciccocioppo R, Forte M, Galipeau J, Ikonomou L, Levine BL, Srivastava A, Zettler PJ (2022) Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products. Cytotherapy 24:686–690

    Article  PubMed  Google Scholar 

  16. De Rosa L, Enzo E, Zardi G, Bodemer C, Magnoni C, Schneider H, De Luca M (2021) Hologene 5: a phase II/III clinical trial of combined cell and gene therapy of junctional epidermolysis bullosa. Front Genet 12:705019

    Article  PubMed  PubMed Central  Google Scholar 

  17. DeVeaux SA, Ogle ME, Vyshnya S, Chiappa NF, Leitmann B, Rudy R, Day A, Mortensen LJ, Kurtzberg J, Roy K, Botchwey EA (2022) Characterizing human mesenchymal stromal cells’ immune-modulatory potency using targeted lipidomic profiling of sphingolipids. Cytotherapy 24:608–618

    Article  CAS  PubMed  Google Scholar 

  18. Dinc G, Ulman YI (2007) The introduction of variolation ‘A La Turca’ to the West by Lady Mary Montagu and Turkey’s contribution to this. Vaccine 25:4261–4265

    Article  PubMed  Google Scholar 

  19. Dolgin E (2021) The tangled history of mRNA vaccines. Nature 597:318–324

    Article  CAS  PubMed  Google Scholar 

  20. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317

    Article  CAS  PubMed  Google Scholar 

  21. Fears R, Akutsu H, Alentajan-Aleta LT, Caicedo A, Campos de Carvalho AC, Čolić M, Cornish J, Cossu G, Debré P, Dierckxsens G, El-Badri N, Griffin G, Chingo-Ho Hsieh P, Inamdar MS, Kumar P, Abraham CM, Maciulaitis R, Al Mahtab M, O’Brien FJ, Pepper MS, Meulen VT (2021) Inclusivity and diversity: integrating international perspectives on stem cell challenges and potential. Stem Cell Reports 16:1847–1852

    Article  PubMed  PubMed Central  Google Scholar 

  22. Fernández-Santos M, García-Arranz M, Andreu E, García-Hernández A, López-Parra M, Villarón E, Sepúlveda P, Fernández-Avilés F, García-Olmo D, Prosper F, Sánchez-Guijo F, Moraleda JM, Zapata A (2022) Optimization of mesenchymal stromal cell (MSC) manufacturing processes for a better therapeutic outcome. Front Immunol 13:918565

    Article  PubMed  PubMed Central  Google Scholar 

  23. Galipeau J, Krampera M, Leblanc K, Nolta JA, Phinney DG, Shi Y, Tarte K, Viswanathan S, Martin I (2021) Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition. Cytotherapy 23:368–372

    Article  CAS  PubMed  Google Scholar 

  24. García-Muñoz E, Vives J (2021) Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use. Cytotechnology 73:1–10

    Article  Google Scholar 

  25. Gonzalez-Vilchis RA, Piedra-Ramirez A, Patiño-Morales CC, Sanchez-Gomez C, Beltran-Vargas NE (2022) Sources, characteristics, and therapeutic applications of mesenchymal cells in tissue engineering. Tissue Eng Regen Med 19:325–361

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Han ZC, Du WJ, Han ZB, Liang L (2017) New insights into the heterogeneity and functional diversity of human mesenchymal stem cells. Biomed Mater Eng 28:S29–S45

    CAS  PubMed  Google Scholar 

  27. Hirsch T, Rothoeft T, Teig N, Bauer JW, Pellegrini G, De Rosa L, Scaglione D, Reichelt J, Klausegger A, Kneisz D, Romano O, Secone Seconetti A, Contin R, Enzo E, Jurman I, Carulli S, Jacobsen F, Luecke T, Lehnhardt M, Fischer M, Kueckelhaus M, Quaglino D, Morgante M, Bicciato S, Bondanza S, De Luca M (2017) Regeneration of the entire human epidermis using transgenic stem cells. Nature 551:327–332

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Iglesias-Lopez C, Obach M, Vallano A, Agustí A (2021) Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Cytotherapy 23:261–274

    Article  CAS  PubMed  Google Scholar 

  29. Jayaraman P, Lim R, Ng J, Vemuri MC (2021) Acceleration of translational mesenchymal stromal cell therapy through consistent quality GMP manufacturing. Front Cell Dev Biol 9:648472

    Article  PubMed  PubMed Central  Google Scholar 

  30. Johnston J, Baylis F, Greely HT (2021) ISSCR: grave omission of age limit for embryo research. Nature 594:495

    Article  CAS  PubMed  Google Scholar 

  31. Kaffash Farkhad N, Sedaghat A, Reihani H, Adhami Moghadam A, Bagheri Moghadam A, Khadem Ghaebi N, Khodadoust MA, Ganjali R, Tafreshian AR, Tavakol-Afshari J (2022) Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial. Stem Cell Res Ther 13:283

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kidpun P, Ruanglertboon W, Chalongsuk R (2022) State-of-the-art knowledge on the regulation of advanced therapy medicinal products. Per Med 19:251

    Article  CAS  PubMed  Google Scholar 

  33. Kirkham AM, Bailey AJM, Monaghan M, Shorr R, Lalu MM, Fergusson DA, Allan DS (2022) Updated living systematic review and meta-analysis of controlled trials of mesenchymal stromal cells to treat COVID-19: a framework for accelerated synthesis of trial evidence for rapid approval-FASTER approval. Stem Cells Transl Med 11:675–687

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kirkham AM, Monaghan M, Bailey AJM, Shorr R, Lalu MM, Fergusson DA, Allan DS (2022) Mesenchymal stem/stromal cell-based therapies for COVID-19: first iteration of a living systematic review and meta-analysis: MSCs and COVID-19. Cytotherapy 24:639–649

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Knezevic I, Mattiuzzo G, Page M, Minor P, Griffiths E, Nuebling M, Moorthy V (2021) WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe 3:e235

    Article  PubMed  Google Scholar 

  36. Langrzyk A, Nowak WN, Stępniewski J, Jaźwa A, Florczyk-Soluch U, Józkowicz A, Dulak J (2018) Critical view on mesenchymal stromal cells in regenerative medicine. Antioxid Redox Signal 29:169–190

    Article  CAS  PubMed  Google Scholar 

  37. Laurencin CT, McClinton A (2020) Regenerative cell-based therapies: cutting edge, bleeding edge, and off the edge. Regen Eng Transl Med 6:78–89

    Article  PubMed  PubMed Central  Google Scholar 

  38. Lavrentieva A, Hoffmann A, Lee-Thedieck C (2020) Limited potential or unfavorable manipulations? Strategies toward efficient mesenchymal stem/stromal cell applications. Front Cell Dev Biol 8:316

    Article  PubMed  PubMed Central  Google Scholar 

  39. Leask F (2019) Spotting ‘unproven’ stem cell therapies in the wild. BioTechniques 67:253

    Article  CAS  PubMed  Google Scholar 

  40. Levine BL, Munsie M, Levine AD, Ikonomou L, International SFCGTCOTEOCAGT (2022) The peril of the promise of speculative cell banking: statement from the ISCT Committee on the Ethics of Cell and Gene Therapy. Cytotherapy 24:977–978

    Article  PubMed  Google Scholar 

  41. Lim F (2021) Proven and unproven cell therapies – what we have learned so far. ISBT Sci Ser 16:213–218

    Article  Google Scholar 

  42. Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, Moore Z, Zeng D (2022) Effectiveness of Covid-19 vaccines over a 9-month period in North Carolina. N Engl J Med 386:933–941

    Article  CAS  PubMed  Google Scholar 

  43. Lipat AJ, Cottle C, Pirlot BM, Mitchell J, Pando B, Helmly B, Kosko J, Rajan D, Hematti P, Chinnadurai R (2022) Chemokine assay matrix defines the potency of human bone marrow mesenchymal stromal cells. Stem Cells Transl Med 11(9):971–986

    Article  PubMed  PubMed Central  Google Scholar 

  44. Lovell-Badge R (2021) Stem-cell guidelines: why it was time for an update. Nature 593:479–479

    Article  CAS  PubMed  Google Scholar 

  45. Manoharan R, Kore RA, Mehta JL (2022) Mesenchymal stem cell treatment for hyperactive immune response in patients with COVID-19. Immunotherapy 14:1055

    Article  CAS  PubMed  Google Scholar 

  46. Markov A, Thangavelu L, Aravindhan S, Zekiy AO, Jarahian M, Chartrand MS, Pathak Y, Marofi F, Shamlou S, Hassanzadeh A (2021) Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders. Stem Cell Res Ther 12:192

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Master Z, Smith C, Tilburt JC (2020) Informed consent for stem cell–based interventions. JAMA 323:893–893

    Article  PubMed  Google Scholar 

  48. Moody J, Milligan WD, St Onge M, Goonewardene A, Rivers P (2021) Cell and gene therapy: a snapshot of investor perspectives. Cytotherapy 23:256–260

    Article  PubMed  Google Scholar 

  49. Morabia A (2018) Edward Jenner’s 1798 report of challenge experiments demonstrating the protective effects of cowpox against smallpox. J R Soc Med 111:255

    Article  PubMed  PubMed Central  Google Scholar 

  50. Mousaei Ghasroldasht M, Seok J, Park HS, Liakath Ali FB, Al-Hendy A (2022) Stem cell therapy: from idea to clinical practice. Int J Mol Sci 23:2850

    Article  PubMed  PubMed Central  Google Scholar 

  51. Ocansey DKW, Pei B, Yan Y, Qian H, Zhang X, Xu W, Mao F (2020) Improved therapeutics of modified mesenchymal stem cells: an update. J Transl Med 18:42

    Article  PubMed  PubMed Central  Google Scholar 

  52. Ofiteru AM, Becheru DF, Gharbia S, Balta C, Herman H, Mladin B, Ionita M, Hermenean A, Burns JS (2020) Qualifying osteogenic potency assay metrics for human multipotent stromal cells: TGF-β2 a telling eligible biomarker. Cells 9:E2559

    Article  Google Scholar 

  53. Pellegrini G, Lambiase A, Macaluso C, Pocobelli A, Deng S, Cavallini G, Esteki R, Rama P (2016) From discovery to approval of an advanced therapy medicinal product-containing stem cells, in the EU. Regen Med 11:407

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Pilishvili T, Gierke R, Fleming-Dutra KE et al (2021) Effectiveness of mRNA Covid-19 vaccine among U.S. health care personnel. N Engl J Med 385:e90

    Article  CAS  PubMed  Google Scholar 

  55. Pimpaneau V, Gianelli F, Trouvin JH, Poiseau AD (2015) The challenges of potency assay development for cell-based medicinal products in Europe. Regul Rapp 12:5–10

    Google Scholar 

  56. Priesner C, Hildebrandt M (2022) Advanced therapy medicinal products and the changing role of academia. Transfus Med Hemother 49:158

    Article  PubMed  PubMed Central  Google Scholar 

  57. Rama P, Matuska S, Paganoni G, Spinelli A, De Luca M, Pellegrini G (2010) Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med 363:147–155

    Article  CAS  PubMed  Google Scholar 

  58. Renesme L, Pierro M, Cobey KD, Mital R, Nangle K, Shorr R, Lalu MM, Thébaud B (2022) Definition and characteristics of mesenchymal stromal cells in preclinical and clinical studies: a scoping review. Stem Cells Transl Med 11:44–54

    Article  PubMed  PubMed Central  Google Scholar 

  59. Riedel S (2005) Edward Jenner and the history of smallpox and vaccination. Bayl Univ Med Cent Proc 18:21–25

    Article  Google Scholar 

  60. Rojewski MT, Weber BM, Schrezenmeier H (2008) Phenotypic characterization of mesenchymal stem cells from various tissues. Transfus Med Hemother 35:168–184

    Article  PubMed  PubMed Central  Google Scholar 

  61. Ruoss S, Walker JT, Nasamran CA, Fisch KM, Paez CJ, Parekh JN, Ball ST, Chen JL, Ahmed SS, Ward SR (2021) Strategies to identify mesenchymal stromal cells in minimally manipulated human bone marrow aspirate concentrate lack consensus. Am J Sports Med 49:1313–1322

    Article  PubMed  PubMed Central  Google Scholar 

  62. Sadeghi B, Roshandel E, Pirsalehi A, Kazemi S, Sankanian G, Majidi M, Salimi M, Aghdami N, Sadrosadat H, Samadi Kochaksaraei S, Alaeddini F, Ringden O, Hajifathali A (2021) Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidua stromal cells. J Cell Mol Med 25:10554–10564

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Saleh A, Qamar S, Tekin A, Singh R, Kashyap R (2021) Vaccine development throughout history. Cureus 13:e16635

    PubMed  PubMed Central  Google Scholar 

  64. Sanyal G (2022) Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies. npj Vaccines 7:1–10

    Article  Google Scholar 

  65. Sanyal G, Särnefält A, Kumar A (2021) Considerations for bioanalytical characterization and batch release of COVID-19 vaccines. npj Vaccines 6:53

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Schneider CK, Celis P, (CAT) TCFAT (2010) Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 9:195–201

    Article  CAS  PubMed  Google Scholar 

  67. Schneider RS, Vela AC, Williams EK, Martin KE, Lam WA, García AJ (2022) High-throughput on-chip human mesenchymal stromal cell potency prediction. Adv Healthc Mater 11:e2101995

    Article  PubMed  Google Scholar 

  68. Shin EY, Yoon YJ, Lee JE, Shim SH, Park GH, Lee DR (2021) Identification of putative markers that predict the in vitro senescence of mesenchymal progenitor cells. Cells 10:1301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S, Luca MD, Kent A, McCabe C, Munsie M, Sleeboom-Faulkner M, Sugarman J, Zimmeren EV, Zarzeczny A, Rasko J (2017) Marketing of unproven stem cell–based interventions: a call to action. Sci Transl Med 9:eaag0426

    Article  PubMed  Google Scholar 

  70. Skibber MA, Olson SD, Prabhakara KS, Gill BS, Cox CS (2022) Enhancing mesenchymal stromal cell potency: inflammatory licensing via mechanotransduction. Front Immunol 13:874698

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Smith KA (2011) Edward jenner and the small pox vaccine. Front Immunol 2:21

    Article  PubMed  PubMed Central  Google Scholar 

  72. Srinivasan A, Sathiyanathan P, Yin L, Liu TM, Lam A, Ravikumar M, Smith RAA, Loh HP, Zhang Y, Ling L, Ng SK, Yang YS, Lezhava A, Hui J, Oh S, Cool SM (2022) Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion. Cytotherapy 24:456–472

    Article  CAS  PubMed  Google Scholar 

  73. Sugarman J, Barker R, Charo R (2019) A professional standard for informed consent for stem cell therapies. JAMA 322:1651

    Article  PubMed  Google Scholar 

  74. Szebeni J, Storm G, Ljubimova JY, Castells M, Phillips EJ, Turjeman K, Barenholz Y, Crommelin DJA, Dobrovolskaia MA (2022) Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines. Nat Nanotechnol 17:337–346

    Article  CAS  PubMed  Google Scholar 

  75. Turner L (2020) Preying on public fears and anxieties in a pandemic: businesses selling unproven and unlicensed “stem cell treatments” for COVID-19. Cell Stem Cell 26:806

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Uberti B, Plaza A, Henríquez C (2022) Pre-conditioning strategies for mesenchymal stromal/stem cells in inflammatory conditions of livestock species. Front Vet Sci 9:806069

    Article  PubMed  PubMed Central  Google Scholar 

  77. Viswanathan S, Shi Y, Galipeau J, Krampera M, Leblanc K, Martin I, Nolta J, Phinney DG, Sensebe L (2019) Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy 21:1019–1024

    Article  CAS  PubMed  Google Scholar 

  78. Viswanathan S, Ciccocioppo R, Galipeau J (2021) Consensus International Council for Commonality in Blood Banking Automation–International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. Cytotherapy 7:393–395

    Google Scholar 

  79. Wang X, Wang K, Yu M, Velluto D, Hong X, Wang B, Chiu A, Melero-Martin JM, Tomei AA, Ma M (2022) Engineered immunomodulatory accessory cells improve experimental allogeneic islet transplantation without immunosuppression. Sci Adv 8:eabn0071

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Watt SM (2022) The long and winding road: homeostatic and disordered haematopoietic microenvironmental niches: a narrative review. Biomater Transl 3:31

    PubMed  PubMed Central  Google Scholar 

  81. Wiese DM, Wood CA, Braid LR (2022) From vial to vein: crucial gaps in mesenchymal stromal cell clinical trial reporting. Front Cell Dev Biol 10:867426

    Article  PubMed  PubMed Central  Google Scholar 

  82. World Health Organization (1980) The global eradication of smallpox: final report of the Global Commission for the Certification of Smallpox Eradication, Geneva, December 1979. World Health Organization

    Google Scholar 

  83. Yui H, Muto K, Yashiro Y, Watanabe S, Kiya Y, Kamisato A, Inoue Y, Yamagata Z (2022) Comparison of the 2021 International Society for Stem Cell Research (ISSCR) guidelines for “laboratory-based human stem cell research, embryo research, and related research activities” and the corresponding Japanese regulations. Regen Ther 21:46–51

    Article  PubMed  PubMed Central  Google Scholar 

  84. Chan LY, Dass SA, Tye GJ, Imran SAM, Wan Kamarul Zaman WS, Nordin F (2022) CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review. Biomedicines 10:804. https://doi.org/10.3390/biomedicines10040804

  85. Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, Nguyen GH, Le PTT, Hoang VT, Forsyth NR, Heke M, Nguyen LT (2022) Stem cell-based therapy for human diseases. Signal Transduct Target Ther 7:272. https://doi.org/10.1038/s41392-022-01134-4

Download references

Author information

Authors and Affiliations

  1. Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy

    Jorge S. Burns

Authors
  1. Jorge S. Burns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jorge S. Burns .

Editor information

Editors and Affiliations

  1. University of Ferrara, Ferrara, Italy

    Jorge S. Burns

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Burns, J.S. (2023). The Art of Stem Cell-Based Therapy. In: Burns, J.S. (eds) Potency Assays for Advanced Stem Cell Therapy Medicinal Products. Advances in Experimental Medicine and Biology, vol 1420. Springer, Cham. https://doi.org/10.1007/978-3-031-30040-0_1

Download citation

Publish with us

Policies and ethics

Search

Navigation